Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.06
- Piotroski Score 2.00
- Grade Buy
- Symbol (CELC)
- Company Celcuity Inc.
- Price $15.25
- Changes Percentage (-0.72%)
- Change -$0.11
- Day Low $14.83
- Day High $15.39
- Year High $22.19
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $31.50
- High Stock Price Target $39.00
- Low Stock Price Target $24.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.78
- Trailing P/E Ratio -5.14
- Forward P/E Ratio -5.14
- P/E Growth -5.14
- Net Income $-63,779,116
Income Statement
Quarterly
Annual
Latest News of CELC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Celcomdigi Berhad Second Quarter 2024 Earnings: EPS: RM0.035 (vs RM0.029 in 2Q 2023)
Celcomdigi Berhad's revenue remained flat at RM3.12b, with net income up 18% to RM406.0m. Profit margin increased to 13%, and EPS rose to RM0.035. Future revenue growth is forecasted at 2....
By Yahoo! Finance | 2 months ago
